Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2017 Jan-Feb;49(1):4-9.
doi: 10.4103/0253-7613.201037.

Is aura around citicoline fading? A systemic review

Saurabh Agarwal  1 , Bhoomika M Patel  1
Affiliations
Meta-Analysis

Is aura around citicoline fading? A systemic review

Saurabh Agarwal et al. Indian J Pharmacol. 2017 Jan-Feb.

Abstract

Stroke and traumatic brain injury (TBI) are the critical public health and socioeconomic problems throughout the world. At present, citicoline is used as a coadjuvant for the management of acute ischemic stroke (AIS) and TBI in various countries. This systemic review analyzes the beneficial role of citicoline in AIS and TBI. This systemic review is based on "PubMed" and "Science Direct" search results for citicoline role in stroke and TBI. In this systemic review, we included 12 human trials. A meta-analysis was performed on the basis of neurological evaluation, functional evaluation and Glasgow outcome scale, domestic adaptation evaluation outcomes, and cognitive outcome individually. In neurological evaluation, domestic adaptation evaluation, and cognitive outcomes, there was no significant difference in both the citicoline and placebo groups (odds ratio [OR] = 1.04 [0.9-1.2, P = 0.583]; OR = 1.1 [0.94-1.27, P = 0.209]; OR = 0.953 [0.75-1.2, P = 0.691]). In evaluation of functional outcomes, there was significant difference in both groups and OR was 1.18 (1.04-1.34, P = 0.01). Functional outcomes were significantly improved by citicoline, but the positive role of this drug in neurological recovery, domestic adaptation, and cognitive outcomes is still a topic of discussion for future.

Keywords: Acute ischemic stroke recovery; Barthel Index score; Glasgow outcome scale; National Institutes of Health Stroke Scale; citicoline; modified Rankin scale; traumatic brain injury.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Procedure for selection of trials for systemic review
Figure 2
Figure 2
Treatment effect on the recovery of neurological assessment (National Institutes of Health Stroke Scale <1)
Figure 3
Figure 3
Treatment effect on the functional recovery (modified Rankin scale <1 and Glasgow outcome scale >7)
Figure 4
Figure 4
Treatment effect on the recovery of activities of daily living (Barthel Index >95)
Figure 5
Figure 5
Treatment effect on recovery of cognitive functions
See this image and copyright information in PMC

References

    1. Baker WL, Colby JA, Tongbram V, Talati R, Silverman IE, White CM, et al. Neurothrombectomy devices for the treatment of acute ischemic stroke: State of the evidence. Ann Intern Med. 2011;154:243–52. - PubMed
    1. Donnan GA, Fisher M, Macleod M, Davis SM. Stroke. Lancet. 2008;371:1612–23. - PubMed
    1. Derex L, Tomsick TA, Brott TG, Lewandowski CA, Frankel MR, Clark W, et al. Outcome of stroke patients without angiographically revealed arterial occlusion within four hours of symptom onset. AJNR Am J Neuroradiol. 2001;22:685–90. - PMC - PubMed
    1. Maas AI, Stocchetti N, Bullock R. Moderate and severe traumatic brain injury in adults. Lancet Neurol. 2008;7:728–41. - PubMed
    1. Meyers PM, Schumacher HC, Connolly ES, Jr, Heyer EJ, Gray WA, Higashida RT. Current status of endovascular stroke treatment. Circulation. 2011;123:2591–601. - PMC - PubMed

MeSH terms

Substances